Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Only about 20% of cases are diagnosed at an early stage, when ovarian cancer is more treatable.
About Jennifer M. Scalici, M.D.
Jennifer Scalici, M.D., joined Mitchell Cancer Institute (MCI) in 2012 after completing a fellowship in gynecologic oncology at the University of Virginia. As a fellow, she developed an investigator-initiated clinical trial evaluating the use of a novel biomarker for ovarian cancer.
Upon her arrival at MCI, she built a busy clinical practice with an emphasis on minimally invasive and robotic surgery. She is currently participating in research to evaluate a novel, minimally invasive procedure to improve the prognostic value and decrease the morbidity of lymph node dissections in gynecologic malignancies.
Dr. Scalici also continues to conduct basic and translational research in collaboration with other members of the MCI gynecologic team. Her active areas of interest are ovarian carcinogenesis and the development of a novel animal model of ovarian cancer with the goal of improving early detection and prevention strategies.
She is also evaluating the role of estrogen metabolism and obesity in the development of endometrial cancer. Dr. Scalici has presented five abstracts and three oral presentations at national meetings since her arrival at MCI, including a Poster of Exceptional Merit at the American College of Surgeons Annual Congress in 2013.